The WATER study (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) is a prospective randomized U.S. investigational device exemption (IDE) clinical trial evaluating the safety and effectiveness of the AquaBeam System as compared to the current standard of care, transurethral resection of the prostate, or TURP. As of December 2016, the WATER Study has completed patient enrollment, enrolling 184 patients between the ages of 45 and 80 at 17 global sites including sites in the United States, Europe, Australia and New Zealand. For more information, click here.

Peter Gilling, MD, Professor of Surgery at Tauranga Hospital, Tauranga, Bay of Plenty, New Zealand (Co-Principal Investigator for the WATER Study)